Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer
Anixa Biosciences (NASDAQ: ANIX) announced that its CAR-T therapy for ovarian cancer, developed with Moffitt Cancer Center, was featured in Breaking Cancer News. The therapy, exclusively licensed from The Wistar Institute, targets the follicle-stimulating hormone receptor (FSHR) protein found on ovarian cancer cells.
The clinical trial is being led by Dr. Robert Wenham and Dr. Monica Avila from Moffitt Cancer Center. This innovative approach aims to revolutionize ovarian cancer treatment by using the body's immune system to attack tumors directly. The article discusses potential study expansion to evaluate repeat dosing and explores broader implications for CAR-T therapy in solid tumors.
Anixa Biosciences (NASDAQ: ANIX) ha annunciato che la sua terapia CAR-T per il cancro ovarico, sviluppata in collaborazione con il Moffitt Cancer Center, è stata presentata in Breaking Cancer News. La terapia, concessa in licenza esclusiva dall'Istituto Wistar, si concentra sul recettore dell'ormone follicolo-stimolante (FSHR) presente sulle cellule del cancro ovarico.
Lo studio clinico è guidato dal Dr. Robert Wenham e dalla Dr.ssa Monica Avila del Moffitt Cancer Center. Questo approccio innovativo mira a rivoluzionare il trattamento del cancro ovarico utilizzando il sistema immunitario del corpo per attaccare direttamente i tumori. L'articolo discute la potenziale espansione dello studio per valutare dosaggi ripetuti e esplora le implicazioni più ampie della terapia CAR-T nei tumori solidi.
Anixa Biosciences (NASDAQ: ANIX) anunció que su terapia CAR-T para el cáncer de ovario, desarrollada junto con el Moffitt Cancer Center, fue destacada en Breaking Cancer News. La terapia, licenciada exclusivamente del Instituto Wistar, se dirige al receptor de la hormona foliculoestimulante (FSHR) que se encuentra en las células del cáncer de ovario.
El ensayo clínico está siendo liderado por el Dr. Robert Wenham y la Dra. Monica Avila del Moffitt Cancer Center. Este enfoque innovador tiene como objetivo revolucionar el tratamiento del cáncer de ovario utilizando el sistema inmunológico del cuerpo para atacar directamente los tumores. El artículo discute la posible expansión del estudio para evaluar dosis repetidas y explora las implicaciones más amplias de la terapia CAR-T en tumores sólidos.
Anixa Biosciences (NASDAQ: ANIX)는 Moffitt Cancer Center와 공동 개발한 난소암을 위한 CAR-T 치료법이 Breaking Cancer News에 소개되었다고 발표했습니다. 이 치료법은 Wistar Institute에서 독점적으로 라이센스 받은 것으로, 난소암 세포에 존재하는 여포 자극 호르몬 수용체(FSHR) 단백질을 표적으로 합니다.
임상 시험은 Moffitt Cancer Center의 Dr. Robert Wenham과 Dr. Monica Avila가 이끌고 있습니다. 이 혁신적인 접근법은 신체의 면역 시스템을 사용하여 종양을 직접 공격함으로써 난소암 치료를 혁신하는 것을 목표로 합니다. 이 기사는 반복 투여를 평가하기 위한 연구 확장 가능성을 논의하고, 고형 종양에서 CAR-T 치료의 더 넓은 의미를 탐구합니다.
Anixa Biosciences (NASDAQ: ANIX) a annoncé que sa thérapie CAR-T pour le cancer de l'ovaire, développée en collaboration avec le Moffitt Cancer Center, a été présentée dans Breaking Cancer News. La thérapie, licenciée exclusivement de l'Institut Wistar, cible le récepteur de l'hormone folliculo-stimulante (FSHR) trouvé sur les cellules du cancer de l'ovaire.
Le procès clinique est dirigé par le Dr Robert Wenham et la Dr Monica Avila du Moffitt Cancer Center. Cette approche innovante vise à révolutionner le traitement du cancer de l'ovaire en utilisant le système immunitaire du corps pour attaquer directement les tumeurs. L'article discute de l'expansion potentielle de l'étude pour évaluer les doses répétées et explore les implications plus larges de la thérapie CAR-T dans les tumeurs solides.
Anixa Biosciences (NASDAQ: ANIX) gab bekannt, dass ihre CAR-T-Therapie gegen Eierstockkrebs, die in Zusammenarbeit mit dem Moffitt Cancer Center entwickelt wurde, in Breaking Cancer News vorgestellt wurde. Die Therapie, die exklusiv vom Wistar Institute lizenziert ist, zielt auf den follikelstimulierenden Hormonrezeptor (FSHR) ab, der auf Eierstockkrebszellen zu finden ist.
Die klinische Studie wird von Dr. Robert Wenham und Dr. Monica Avila vom Moffitt Cancer Center geleitet. Dieser innovative Ansatz zielt darauf ab, die Behandlung von Eierstockkrebs zu revolutionieren, indem das Immunsystem des Körpers direkt gegen Tumore eingesetzt wird. Der Artikel erörtert die mögliche Erweiterung der Studie zur Bewertung von Wiederholungsdosen und untersucht die breiteren Implikationen der CAR-T-Therapie bei soliden Tumoren.
- Exclusive license for innovative CAR-T therapy targeting ovarian cancer
- Strategic partnership with prestigious Moffitt Cancer Center
- Therapy targets FSHR protein specific to ovarian cancer cells
- Potential for expanded study with repeat dosing
- None.
The article highlights the groundbreaking clinical trial led by Dr. Robert Wenham, Chairman of the Department of Gynecologic Oncology at Moffitt Cancer Center, and Dr. Monica Avila, a leading gynecologic oncologist at Moffitt. The trial explores the use of chimeric antigen receptor-T cell (CAR-T) therapy to treat ovarian cancer, a disease with historically limited treatment options for advanced-stage patients.
The CAR-T therapy being studied in this trial, exclusively licensed to Anixa from The Wistar Institute, and developed through a partnership between Anixa and Moffitt, is designed to target the follicle-stimulating hormone receptor (FSHR), a protein uniquely expressed on ovarian cancer cells. This novel approach has the potential to revolutionize the treatment of ovarian cancer by leveraging the body's immune system to directly attack tumors.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, commented, "We are honored to see our work recognized in Breaking Cancer News and to witness the promising impact this CAR-T therapy is having on patients. Our partnership with Moffitt Cancer Center exemplifies our commitment to developing novel and targeted immunotherapies that could transform the standard of care for some of the most challenging cancers, including ovarian cancer."
The article also highlights the potential expansion of the study to evaluate repeat dosing, given Gallagher's response, and explores the broader implications of CAR-T therapy for solid tumors—an area of intense research and high unmet medical need.
The full article can be accessed here: https://breakingcancernews.com/2025/02/18/navigating-uncharted-territory-car-t-for-ovarian-cancer/.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-featured-in-breaking-cancer-news-article-on-novel-car-t-therapy-for-ovarian-cancer-302383018.html
SOURCE Anixa Biosciences, Inc.
FAQ
What is the target protein for Anixa's (ANIX) ovarian cancer CAR-T therapy?
Who are the lead investigators for Anixa's (ANIX) ovarian cancer CAR-T clinical trial?
Which institution licensed the CAR-T technology to Anixa (ANIX)?
What is the potential expansion plan for Anixa's (ANIX) ovarian cancer CAR-T trial?
How does Anixa's (ANIX) CAR-T therapy work against ovarian cancer?
